Skip Navigation

Cross-Over Technologies

IMAT applications constituted approximately 78 percent of all technology development applications reviewed by the NCI in FY 2005, approximately 61 percent of those reviewed in FY 2006, and 72 percent of those reviewed in FY 2007 (figure 3 below). Based on this report, 415 technology-related R21, R33, and R0l grant applications were reviewed under 5 RFAs in FY 2006, representing a growth rate of 111 percent relative to FY 2002. The explosive growth rate of such applications highlights both the success of the NCI in soliciting innovative technology development proposals and the increasing importance that innovation plays in the cancer research arena. IMAT applications constituted approximately 78 percent of all technology development applications reviewed by the NCI in FY 2005 and approximately 61 percent of those reviewed in 2006. Such data indicate the strength of the IMAT Program's contribution to the NCI's technology development portfolio. Between FY 2005 and FY 2006, the IMAT Program awarded 95 research project grants, 26 of which represented new or first-time awardees. In addition, the program has made 51 awards in FY 2007, 5 to new or first-time awardees.

Technology Applications Reviewed by the National Cancer Institute.

IMAT Contribution to NCI Technology Portfolio

Technology Initiatives Applications Reviewed FY 2004 - 2008

 

Figure 3

IMAT Contributions to the NCI's Technology Development Portfolio as a Function of All Technology Applications Reviewed by the National Cancer Institute

 

Examples of IMAT Investigators Utilizing IMAT-Developed Technologies In Selected NCI Programs

PI Name IMAT Award(s) Alliance for Nanotechnology in Cancer Award Clinical Proteomic Technologies Initiative Award Integrative Cancer Biology Program Award
James Baker
University of Michigan
Photonic Crystal Fiber Probe Fluorescence Biosensing
(R33 CA112141)
DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment    
Xiaolian Gao
University of Houston
Parallel Synthesis of RNA Oligonucleotide Microarrays
(R21 CA084708)
  Proteomic Phosphopeptide Chip Technology for Protein Profiling  
Tim H-M Huang
Ohio State University
Novel Tool for Analysis of Promoter Hypermethylation
(R33 CA094441)
High Throughput Methylation Analysis in Cancer
(R33 CA084701)
    Interrogating Epigenetic Changes in Cancer Genomes
Jan Schnitzer
Sidney Kimmel Cancer Center
Technology/Map Endothelial Targets/Human Renal Tumors
(R33 CA118602)
Technology to Unmask Accessible Tumor Vascular Targets
(R33 CA097528)
Nanotechnology Platform for Targeting Solid Tumors    
Richard D. Smith
Battelle Pacific Northwest Laboratory
Ultra-Sensitive Approach for Monitoring Gene Production
(R33 CA081654)
High Throughput Fticr for Molecular Analysis of Cancer
(R33 CA086340)
  A Proteomics Platform for Quantitative, Ultra-High Throughput, and Ultra-Sensitive  
Paul Tempst
Memorial Sloan-Kettering Cancer Center
Peptide Profiling Techniques to Detect Thyroid Carcinoma
(R21CA111942)
Peptide Profiling Techniques to Detect Thyroid Carcinoma
(R33CA111942)
  CPTAC team  
Benjamin Cravatt
Scripps Research Institute
Microarray Platform for Profiling Cancer Proteases (R33 CA118696)

Transformative R01 (T-R01)

Massively Parallel Identification of Protein Ligands

Shohei Koide
University of Chicago
High-performance affinity reagents for peptide epitopes (R21 CA132700)

Transformative R01 (T-R01)

Rational Generation of Protein Capture Reagents